Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXIUM for maintenance of healing of erosive esophagitis in pediatric patients 1 to 11 years
2023-505454-18-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, single-arm trial of esomeprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Primary endpoints: Maintenance phase endoscopic healing and Maintenance phase safety and tolerability. Started Apr 2024; status: completed.
02
Drugs
esomeprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2023-505454-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505454-18-00.